PT - JOURNAL ARTICLE AU - SOO JIN PARK AU - WHASUN LIM AU - JAEHEE MUN AU - HAERIN PAIK AU - SUNWOO PARK AU - HYUNJI LIM AU - JUNHWAN KIM AU - EUN JI LEE AU - GA WON YIM AU - NARA LEE AU - CHEOL LEE AU - JAE-WEON KIM AU - GWONHWA SONG AU - HEE SEUNG KIM TI - <em>SERPINB11</em> Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary AID - 10.21873/invivo.12547 DP - 2021 Sep 01 TA - In Vivo PG - 2647--2653 VI - 35 IP - 5 4099 - http://iv.iiarjournals.org/content/35/5/2647.short 4100 - http://iv.iiarjournals.org/content/35/5/2647.full SO - In Vivo2021 Sep 01; 35 AB - Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p&lt;0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC.